Glenmark Pharmaceuticals announces Launch of Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, World's First Nebulized Triple Therapy for COPD

Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global pharmaceutical company, today announced the launch of Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, the world's first nebulized, fixed-dose triple therapy for the treatment of Chronic Obstructive Pulmonary Disease (COPD).

Both products combine three proven medicines - Glycopyrronium, Formoterol, and Budesonide - to reduce airway obstruction, inflammation, and improve lung function and symptom control. As a single, easy-to-use nebulized therapy, it minimizes the burden of multiple medications. This marks a breakthrough as a new standard of care for COPD patients, especially those who struggle with using Metered Dose Inhalers (MDI) or Dry Powder Inhalers (DPI).

Commenting on the launch, Mr. Alok Malik, President & Business Head, India Formulations, Glenmark Pharmaceuticals said, "At Glenmark, innovation is about reimagining and redefining how therapies reach patients. With Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, the world's first nebulized triple therapy for COPD, we are transforming respiratory care. This milestone reinforces Glenmark's position as a front-runner in respiratory innovation and our commitment to making advanced, affordable, and accessible solutions for patients."

In a clinical study conducted in India, this nebulized triple therapy demonstrated rapid improvement in lung function and better control of breathlessness (dyspnea) among patients. The treatment was well tolerated and demonstrated a good safety profile, offering patients a simpler and more effective way to manage COPD.

Dr. Monika Tandon, Global Head of Clinical Development, Glenmark Pharmaceuticals, said, "This launch represents a significant advancement in the management of COPD and demonstrates our focus in strengthening global respiratory leadership. Nebulizer medications are easy to use in patients with COPD. The strong efficacy and safety demonstrated in the clinical study further support this novel treatment approach in COPD."

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 1841.05 as compared to the previous close of Rs. 1845.15. The total number of shares traded during the day was 33439 in over 2446 trades.

The stock hit an intraday high of Rs. 1860.60 and intraday low of 1825.00. The net turnover during the day was Rs. 61734201.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 Nebzmart GFBSmartules GlenmarkAirz FBSmartules COPD